- RecruitingPHASE1, PHASE2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
This study is testing a new medicine, nuvisertib, for myelofibrosis. It aims to see if it's safe and how it works, either alone or with ruxolitinib. It's for people whose current treatments aren’t working well.
For: MyelofibrosisUnited States · Australia · Belgium - RecruitingPHASE2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
This study looks at a new drug, selinexor, for people with a bone marrow condition called myelofibrosis. It's for those who haven't tried certain other treatments and have low to normal platelet counts. The main aim is to see if selinexor can shrink an enlarged spleen.
For: Myelofibrosis · Moderate Thrombocytopenia · Mild ThrombocytopeniaUnited States · Belgium · Bulgaria - RecruitingPHASE1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.
For: NeoplasmsUnited States · Canada · France - RecruitingPHASE2
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
This study is testing a new drug called momelotinib for people with a type of blood disorder called low-risk myelodysplastic syndromes (LR-MDS). Researchers want to see if it's safe, helps reduce the need for blood transfusions, and how the body handles the medicine.
For: Myelodysplastic SyndromesUnited States · Canada · France